The new drug Litfulo (ritlecitinib) has reached the Canadian market, while baricitinib (Olumiant) is now approved for alopecia areata and in a new higher-strength tablet.
This new combo product will be used to manage heavy menstrual bleeding associated with uterine fibroids, and moderate to severe pain associated with endometriosis.
Clarivate’s recently released Drugs to Watch 2024 report highlights 13 important drugs and a handful of new technologies that could be transformative this year.